<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="1502">
  <stage>Registered</stage>
  <submitdate>17/12/2003</submitdate>
  <approvaldate>17/12/2003</approvaldate>
  <actrnumber>ACTRN12607000011482</actrnumber>
  <trial_identification>
    <studytitle>HERA (HERceptin Adjuvant) Trial</studytitle>
    <scientifictitle>HERA: A randomised three-arm multi-centre comparison of 1 year and 2 years of Herceptin® versus no Herceptin® in women with HER2-positive primary breast cancer who have completed adjuvant chemotherapy.</scientifictitle>
    <utrn />
    <trialacronym>ANZ 0101 / BIG 1-01</trialacronym>
    <secondaryid>National Clinical Trials Registry: NCTR446</secondaryid>
    <secondaryid>NCT00045032</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Breast Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Breast</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Patients will be randomised upon completion of definitive surgery and systemic adjuvant chemotherapy to receive no Herceptin® or Herceptin® for one year* or two years**. Patients will receive Herceptin by intravenous infusion at a dose of 8mg/kg on day 1, followed by maintenance dose of 6mg/kg three weeks later and  thereafter every three weeks for a total of one or two years, or until disease recurrence.
* 1 year of Herceptin® is defined as 12 calendar months of treatment from day 1 of 1st administration and 18 infusions maximum.
** 2 years of Herceptin® is defined as 24 calendar months of treatment from day 1 of 1st administration and 35 infusions maximum.

If clinically indicated, all ER positive patients can receive systemic adjuvant hormonal therapy. Radiation therapy when indicated must have been completed prior to the start of Herceptin®.</interventions>
    <comparator>1 or 2 years of Herceptin versus no Herceptin.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To compare disease-free survival (DFS) in patients with HER2 overexpressing breast cancer who have been randomised to Herceptin? for one year versus no Herceptin?.</outcome>
      <timepoint>Patients will be reviewed by clinicians for  progression of disease every 3 months for the first 2 years and then 6 monthly in years 3-5 and yearly thereafter until 10 years from randomisation.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>To compare DFS patients with HER2 overexpressing breast cancer who have been randomised to Herceptin? for two years versus no Herceptin?.</outcome>
      <timepoint>Patients will be reviewed by clinicians for  progression of disease every 3 months for the first 2 years and then 6 monthly in years 3-5 and yearly thereafter until 10 years from randomisation.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To compare overall survival (OS) in patients randomised to i) Herceptin? for one year or no further therapy and to ii) Herceptin? for two years or no further therapy.</outcome>
      <timepoint>Patients will be assessed by the clinician for survival, progression of disease, tolerability and side effects, and cardiac function 3 monthly in the first 2 years, 6 monthly years 3 to 5 and yearly thereafter until year 10 from randomisation.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To compare relapse-free survival (RFS), distant disease free survival (DDFS), time to recurrence (TTR), time to distant recurrence (TTDR).</outcome>
      <timepoint>Patients will be assessed by the clinician for survival, progression of disease, tolerability and side effects, and cardiac function 3 monthly in the first 2 years, 6 monthly years 3 to 5 and yearly thereafter until year 10 from randomisation.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To evaluate  the safety and tolerability of Herceptin?</outcome>
      <timepoint>Patients will be assessed by the clinician for survival, progression of disease, tolerability and side effects, and cardiac function 3 monthly in the first 2 years, 6 monthly years 3 to 5 and yearly thereafter until year 10 from randomisation.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To compare the incidence of cardiac dysfunction in patients treated and not treated with Herceptin?.</outcome>
      <timepoint>Patients will be assessed by the clinician for survival, progression of disease, tolerability and side effects, and cardiac function 3 monthly in the first 2 years, 6 monthly years 3 to 5 and yearly thereafter until year 10 from randomisation.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To compare outcomes (DFS, OS, RFS, DDFS, TTR, TTDR, cardiac safety, overall safety) of patients treated with Herceptin ? for one year compared with Herceptin ? for two years.</outcome>
      <timepoint>Patients will be assessed by the clinician for survival, progression of disease, tolerability and side effects, and cardiac function 3 monthly in the first 2 years, 6 monthly years 3 to 5 and yearly thereafter until year 10 from randomisation.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Eastern Cooperative Oncology Group (ECOG) performance status = 1; Non-metastatic operable primary invasive adenocarcinoma of the breast that is: histologically confirmed, adequately excised, axillary node positive or negative, and tumour size =T1c according to TNM; Known hormone receptor status (ER/PgR or ER alone); Patient must have received at least four cycles of an approved (neo-) adjuvant chemotherapy regimen; Baseline LVEF = 55% measured by echocardiography or MUGA scan after completion of all (neo-) adjuvant chemotherapy and radiotherapy); Completion of radiotherapy for any patients undergoing radiotherapy; Overexpression of HER2 in the invasive component of the primary tumour, according to one of the following  definitions: 3+ overexpression by IHC or  2+ overexpression by IHC AND fluorescence in situ hybridisation (FISH) test demonstrating c-erbB2 gene amplification, or c-erbB2 gene amplification by FISH; Completion of all necessary baseline lab and radiologic investigations; Signed written informed consent</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>History of any prior (ipsi- and/or contralateral) invasive breast carcinoma; Past or current history of malignant neoplasms, except for curative treated: basal and squamous cell carcinoma of the skin, in situ carcinoma of the cervix; Any clinical T4 tumour, including inflammatory breast cancer;  Maximum cumulative dose of doxorubicin &gt;360mg/m2 or maximum cumulative dose epirubicin &gt; 720mg/m2 or any prior anthracyclines unrelated to the present breast cancer; (Neo-) or adjuvant chemotherapy using peripheral stem cell or bone marrow stem cell support; Any prior mediastinal irradiation except internal mammary node irradiation for the present breast cancer; Patients with positive or suspicious internal mammary nodes identified by sentinel node technique which have not been irradiated or patients with supraclavicular lymph node involvement; Prior use of anti-HER2 therapy for any reason or other prior biologic or immunotherapy for breast cancer; Concurrent anti-cancer treatment in another investigational trial, including hormone therapy, immunotherapy, and bisphosphonate therapy; Serious cardiac illness or medical conditions including but not confined to: History of documented congestive heart failure (CHF), high-risk uncontrolled arrythmias, angina pectoris requiring antianginal medication, clinically significant valvular heart disease, evidence of transmural infarction on ECG, poorly controlled hypertension; Other concurrent serious diseases that may interfere with planned treatment including severe pulmonary conditions/illness; Any of the following abnormal laboratory tests immediately prior to randomisation: serum bilirubin &gt; 2.0 x upper limit of normal (ULN), alanine amino transferase (ALAT) or aspartate amino transferase (ASAT) &gt; 2.5 x ULN, alkaline phosphatase (ALP) &gt; 2.5 x ULN, serum creatinine &gt; 2.0 x ULN, total white blood cell count (WBC) &lt; 2500/mm3, absolute neutrophil count &lt; 1500/mm3, platelets &lt;100,000/mm3; Pregnant or lactating women; Women of childbearing potential or less than one year after menopause (unless surgically sterile) who are unable or unwilling to use adequate contraceptive measures during study treatment.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Central randomisation by phone/fax</concealment>
    <sequence>computer generated stratified block</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>non-blinded</designfeatures>
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>1/12/2001</anticipatedstartdate>
    <actualstartdate>1/07/2002</actualstartdate>
    <anticipatedenddate />
    <actualenddate>1/01/2005</actualenddate>
    <samplesize>4482</samplesize>
    <actualsamplesize>5102</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>4/01/2016</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>F.Hoffmann-La Roche Ltd</primarysponsorname>
    <primarysponsoraddress>Konzern-Hauptsitz
Grenzacherstrasse 124
CH-4070 Basel</primarysponsoraddress>
    <primarysponsorcountry>Switzerland</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname>BIG (Breast International Group)</fundingname>
      <fundingaddress>Blvd de Waterloo 121
B-1000 Brussels</fundingaddress>
      <fundingcountry>Belgium</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>F.Hoffmann-La Roche Ltd</fundingname>
      <fundingaddress>Konzern-Hauptsitz
Grenzacherstrasse 124
CH-4070 Basel</fundingaddress>
      <fundingcountry>Switzerland</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Other Collaborative groups</sponsortype>
      <sponsorname>Breast International Group</sponsorname>
      <sponsoraddress>Blvd de Waterloo 121
B-1000 Brussels</sponsoraddress>
      <sponsorcountry>Belgium</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The best treatment for some women with early breast cancer includes a few months of chemotherapy after their surgery.  However, even with the best treatment, the cancer sometimes re-occurs.  Trastuzumab, also known as Herceptin, is a new drug that targets breast cancer cellls that have a special receptor (HER2) on them.  Trastuzumab is benefical for women with advanced breast cancers that have HER2.  This large, international trial will determine if adding Trastuzumab to best standard treatment improves cure rates for women with early breast cancers with HER2.  It will also determine whether it is better to continue treatment with Trastuzumab for 1 or 2 years.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Auckland Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Austin Health</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Border Medical Oncology</ethicname>
      <ethicaddress />
      <ethicapprovaldate>1/12/2001</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Box Hill Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Christchurch Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Dunedin Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Frankston Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Liverpool Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Maroondah Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Mater Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Mercey Private</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Newcastle Mater Misericordiae Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Palmerston North Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Peter MacCallum Cancer Centre</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Queen Elizabeth Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Melbourne Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Sir Charles Gairdner Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Wellington Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Western Hosptial</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Westmead Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>John F Forbes</name>
      <address>ANZBCTG
PO BOX 155
HRMC NSW 2310</address>
      <phone>+61 2 4985 0113</phone>
      <fax>+61 2 4960 1539</fax>
      <email>enquiries@anzbctg.org</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Corinna Beckmore</name>
      <address>ANZBCTG
PO BOX 155
HRMC NSW 2310</address>
      <phone>+61 2 4985 0159</phone>
      <fax>+61 2 49850141</fax>
      <email>enquiries@anzbctg.org</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Nicholas Wilcken</name>
      <address>Department of Medical Oncology &amp; Palliative Care
Westmead Hospital
Darcy Road (cnr Hawkesbury Road)
WESTMEAD  NSW  2145</address>
      <phone>+61 (02) 9845-5200</phone>
      <fax />
      <email>enquiries@anzbctg.org</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>